The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.

The firm will use the funding to advance ongoing clinical trials of its autologous cell therapies for solid tumors.

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application by year end ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...

The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...

The biotech wants to create one-time, potentially curative treatments for rheumatoid arthritis and other autoimmune diseases by editing the HLA gene.